ovarian serous carcinoma in specialized care center in Montréal (Québec, CANADA) from 1999 to 2019. Neighborhood socioeconomic status at diagnosis for each woman was inferred from their postal code area linked to socioeconomic indicators derived from the Canadian census data. Immunological age was measured using a forensic medicine validated blood biomarker (TRECs – T-cell receptor excision circles). Blood sample were available before treatments (n = 196), after treatments (n = 270), or paired before and after treatments (n = 22). Time was calculated from diagnosis date to death, relapse or study censoring (last relapse-free follow-up date).

Result(s)* In our study sample, neighborhood socioeconomic status at diagnosis did not affect overall survival. We observed that accelerated immunological aging was occurring before treatment initiation (n = 218, p < 0.0001). Treatment itself was not associated with a significant additional accelerated immunoaging (n = 22). Neither higher FIGO stage at diagnosis nor neighborhood socioeconomic status at diagnosis were associated with a higher disparity between chronological and immunological age.

Conclusion* Our preliminary study results support that either cancer itself causes a significant immunological age shift in women suffering from a primary ovarian serous carcinoma, or that women suffering from accelerated aging are more prone to develop cancer. Although statistical underpower and a biased sample effect cannot be excluded, the socioeconomic status does not seem to influence accelerated immunoaging nor overall survival.

**850** CLINICAL MANAGEMENT AND OUTCOMES OF PRIMARY OVARIAN SARCOMAS – A SINGLE CENTER EXPERIENCE


10.1136/ijgc-2021-ESGO.485

Introduction/Background* Primary ovarian sarcoma is a very rare malignancy representing <2% of ovarian cancer. Aim of this study is to investigate the clinicopathologic features and outcomes in patients with primary sarcoma of the ovary.

Methodology We retrospectively reviewed between 2012 and 2019, all patients with primary ovarian sarcoma who were treated at Alexandra Hospital of Athens.

Result(s)* A total of 17 patients with ovarian sarcoma had been surgically treated. The median age of patients was 61 [33-84] years. The most common symptom was abdominal pain and bloating. The majority of patients were postmenoausal (14) and only three were premenopausal. The histopathological diagnosis revealed 14 patients with carcinosarcoma, two with ovarian endometrial stromal sarcoma and one with leiomyosarcoma. After the surgery 23% of patients were at stage I, 12% at stage II, 53% at stage III and 12% at stage IV. Only 5 (29%) patients had suboptimal debulking surgery and 12 (71%) had optimal debulking surgery. The mean number of chemotherapy courses were 6.8 ± 4 with unsatisfactory response. Five patients had a recurrence at two years and 4 of them had a secondary debulking surgery.

Conclusion* Primary ovarian sarcoma has a poor prognosis. Optimal debulking surgery appears to be a significant factor for recurrence. There is a need for more studies to explore the role of optimal debulking surgery and adjuvant chemotherapy in primary ovarian sarcoma.